Article
Immunology
Andrew D. Wiese, Ed Mitchel, Danielle Ndi, Tiffanie M. Markus, H. Keipp Talbot, William Schaffner, Carlos G. Grijalva
Summary: This study analyzed the association between invasive pneumococcal disease (IPD) and acute myocardial infarction (AMI) and found a significant increase in the risk of AMI during periods associated with laboratory-confirmed IPD.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Kristiana Alexandrova Nikolova, Mikael Andersson, Hans-Christian Slotved, Anders Koch
Summary: The introduction of PCV13 in Greenland's childhood vaccination program in 2010 led to a decrease in overall incidence rates of IPD, with a significant decrease in children but a notable increase among the elderly. The incidence of vaccine serotype IPD decreased across all ages, while non-vaccine serotype IPD increased during the post-PCV13 period, particularly among the elderly aged 60 years and above. Continued surveillance of IPD in the Greenlandic population is needed to monitor the trend.
Article
Immunology
Rameela Raman, Julia Brennan, Danielle Ndi, Chantel Sloan, Tiffanie M. Markus, William Schaffner, H. Keipp Talbot
Summary: The introduction of PCV13 was found to be associated with substantial reductions in overall incidence and socioeconomic and racial disparities in PCV13-serotype incidence.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Letter
Infectious Diseases
Paulo Camargos, Eliane Drumond, Cristiana M. Nascimento-Carvalho
Summary: The reduction in pneumococcal meningitis was not solely attributed to PCV implementation, but may also be influenced by various factors such as socioeconomic and healthcare improvements. Furthermore, the uncertainty in diagnosing the etiology of meningitis may limit the assessment of missed cases of pneumococcal meningitis, hindering the evaluation of PCV efficacy.
LANCET INFECTIOUS DISEASES
(2021)
Article
Immunology
Robert Cohen, Corinne Levy, Naim Ouldali, Marie Goldrey, Stephane Bechet, Stephane Bonacorsi, Emmanuelle Varon
Summary: Most non-PCV13 serotypes had low invasive disease potential, while among serotypes with the highest invasive disease potential, most are included in PCV20 vaccine.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Marta Bertran, Zahin Amin-Chowdhury, Carmen L. Sheppard, Seyi Eletu, Dania Zamarreno, Mary E. Ramsay, David Litt, Norman K. Fry, Shamez N. Ladhani
Summary: In England, after the removal of COVID-19 restrictions in July-December 2021, the incidence of invasive pneumococcal disease in children under 15 years old was higher compared to the same period in 2020 and the pre-pandemic years of 2017-2019. This highlights the potential risk following the relaxation of COVID-19 restrictions, emphasizing the need to maintain childhood vaccine coverage to protect the population.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Immunology
Lindsay R. Grant, Mary P. E. Slack, Christian Theilacker, Jelena Vojicic, Stephane Dion, Ralf Rene Reinert, Luis Jodar, Bradford D. Gessner
Summary: The distribution of pneumococcal serotypes in children from high-income countries has been examined. Much of the burden of invasive pneumococcal disease (IPD) is caused by serotypes in PCV15 and PCV20; including these pneumococcal conjugate vaccines (PCVs) into existing pediatric immunization programs may help reduce the incidence of IPD.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Jana Kozakova, Pavla Krizova, Marek Maly
Summary: The study analyzed the impact of PCV vaccination on the incidence of IPD in children under 5 years old in the Czech Republic. Results showed a significant decrease in IPD incidence after PCV vaccination, but ongoing surveillance is important to monitor for potential serotype replacement.
Article
Immunology
Juan Buades, Ines Losada, Juan Gonzalez-Moreno, Maria Penaranda, Laia Vilaplana, Nuria Roda, Adelaida Rey, Adrian Rodriguez, Margarita Garau, Enrique Ruiz de Gopegui, Antoni Serra, Juan Saurina, Antoni Payeras
Summary: This study compared the evolution, clinical, and microbiological characteristics of invasive pneumococcal disease (IPD) in the adult population of Majorca before and after the introduction of PCV-13 vaccine. The research found a decrease in the proportion of IPD caused by vaccinal serotypes included in the PCV-13 vaccine during the second period.
Article
Immunology
Pilar Ciruela, Nuria Soldevila, Juan Jose Garcia-Garcia, Sebastia Gonzalez-Peris, Alvaro Diaz-Conradi, Alba Redin, Belen Vinado, Conchita Izquierdo, Carmen Munoz-Almagro, Angela Dominguez
Summary: This study analyzed the impact of COVID-19 on healthcare demand and invasive pneumococcal disease in children in Catalonia, Spain. It found significant reductions in healthcare activities and incidence of invasive pneumococcal disease in 2020 compared to 2018-2019, likely due to the implementation of nonpharmaceutical measures during the COVID-19 pandemic.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Immunology
Hector F. Africano, Cristian C. Serrano-Mayorga, Paula C. Ramirez-Valbuena, Ingrid G. Bustos, Alirio Bastidas, Hernan A. Vargas, Sandra Gomez, Alejandro Rodriguez, Carlos J. Orihuela, Luis F. Reyes
Summary: This study found that MACE are common during IPD, with serotypes 3 and 9n independently associated with MACE, regardless of their frequency. Bacteremia occurred in a high percentage of patients with MACE, and MACE patients had significantly elevated serum concentrations of C-reactive protein compared to non-MACE patients.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Microbiology
John A. Branda, Allen C. Steere
Summary: Lyme borreliosis is caused by a complex group of spirochetes, leading to various clinical manifestations and possible long-term sequelae. Laboratory diagnosis, focused on in this review, requires a deep understanding for accurate interpretation, with serologic testing remaining essential due to the limitations of direct pathogen detection. Despite some advancements, there are promising prospects for future assay development in Lyme borreliosis diagnostics.
CLINICAL MICROBIOLOGY REVIEWS
(2021)
Article
Immunology
Andrew Anglemyer, Andrea McNeill, Kara DuBray, Gerard J. B. Sonder, Tony Walls
Summary: New Zealand's shift from PCV13 to PCV10 has led to an increasing number of serotype 19A cases in young children and a rise in penicillin-resistant isolates. It is necessary for NZ to reconsider its choice of pneumococcal vaccine.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Stephanie Perniciaro, Mark van der Linden, Daniel M. Weinberger
Summary: The incidence of invasive pneumococcal disease (IPD) in Germany showed a declining trend in 2020-2021 under the influence of nonpharmaceutical interventions (NPIs), but exhibited variations in age and serotype specificity over time.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Jade L. L. Teng, Kenny M. N. Fok, Ken P. K. Lin, Elaine Chan, Yuanchao Ma, Susanna K. P. Lau, Patrick C. Y. Woo
Summary: Hong Kong has achieved a more substantial decrease in the incidence of invasive pneumococcal disease compared to other countries, most likely due to the widespread adoption of face masks by the public. Human behavioral changes, particularly mask wearing, should be considered as an additional preventive strategy against invasive pneumococcal disease.
CLINICAL INFECTIOUS DISEASES
(2022)